Evolving Adjuvant Treatments for HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
EP. 1: Prognosis and Survival Outcomes for HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
EP. 2: Evolving and Current Standards of Care for HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
EP. 3: AE Management With Neratinib in HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
EP. 4: Unmet Needs in HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.
EP. 5: Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
EP. 6: Ongoing Research Efforts in HER2+ Early Breast Cancer
Megan Kruse, MD, of Cleveland Clinic
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.
